Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Drivers of revenue growth included more customers using multiple chronic condition programs as well as strong adoption of GLP ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $250 billion in annual US healthcare distribution sales, the company supplies ...

Revenue reached $67.2 billion, beating analyst estimates by 7.3% (non-GAAP) and growing 11% year over year. Adjusted earnings per share (EPS) rose to $7.20, surpassing expectations and EPS increased 7 ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

Cigna has sold its Medicare businesses and slashed the number of people it covers in its ACA plans by more than half.

Full year 2025 pretax adjusted earnings outlooks for Evernorth and Cigna Healthcare remain at "at least $7.2 billion" and "at least $4.125 billion" respectively. The company expects the full year ...

CVS Health Corporation (NYSE:CVS) is one of the largest pharmaceutical retailers in America.